Valuation dashboard for Organon & Co. (OGN) with P/E 17.31, P/B 3.57, EV/EBITDA 7.87 and dividend yield 0.59%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio).
Analysis Summary
Organon & Co. reported revenue of $6.22B in the most recent fiscal year, growing at a 5-year CAGR of -1.0%. Net income reached $187.0M, with a -38.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 53.0%, operating margin 19.3%, net margin 3.4%.
At the current price of $13.67, OGN trades at a P/E of 17.31 and an ROE of 24.87%. Market capitalisation stands at $3.6B.
Balance sheet quality for OGN: current ratio of 1.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 17.31 |
| Price / Book | 3.57 |
| EV / EBITDA | 7.87 |
| Dividend Yield | 0.59% |
Valuation Models
| DCF Fair Value | $30.58 |
| vs Current Price | +123.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| OGN | Organon & Co. | $3.6B | 17.31 | 3.57 | 24.9% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.2B | 7.19 | 3.59 | 59.0% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.4B | 13.49 | 2.45 | 20.1% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.8B | 45.71 | 12.38 | |
| MD | Pediatrix Medical Group, Inc. | $2.2B | 12.65 | 2.41 | |
| NUVB | Nuvation Bio Inc. | $2.0B | 7.68 | -66.9% |
Price
| Price | $13.67 |
| Market Cap | $3.6B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 24.87% |
| Return on Invested Capital | 5.37% |
| Return on Assets | 1.45% |
| Gross Margin | 52.98% |
| Operating Margin | 19.29% |
| Net Margin | 3.41% |
Related companies: ALVO · AUPH · AVDL · GRDN · HRMY · MD · NUVB
Explore sector: Healthcare · Drug Manufacturers - General
More sections of OGN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks